Patient characteristics
| Hematological malignancy N (%) | No hematological malignancy N (%) | P value | |
| MM (total) | 52 (100%) | 257 (100%) | |
| Gender | 0.23 | ||
| Male | 37 (71.2%) | 157 (61.1%) | |
| Female | 15 (28.8%) | 100 (38.9%) | |
| Age at diagnosis of skin cancer | n.s. | ||
| Median (IQR) | 72.5 years (59.0–76.0) | 67.0 years (53.0–75.0) | |
| Primary site of skin cancer | 0.38 | ||
| Head and neck | 13 (23.1%) | 51 (19.8%) | |
| Trunk | 21 (40.4%) | 97 (37.7%) | |
| Extremities | 12 (23.1%) | 48 (18.6%) | |
| Mucosa/others | 2 (3.8%) | 27 (10.4%) | |
| Unknown primary | 4 (7.6%) | 34 (13.2%) | |
| Median follow-up time (months, IQR) | 8.7 (3.9–23.8) | 15.0 (6.0–28.0) | n.s. |
| cSCC (total) | 15 (100%) | 59 (100%) | |
| Gender | |||
| Male | 12 (80%) | 41 (69%) | 0.65 |
| Female | 3 (20%) | 18 (31%) | |
| Age at diagnosis of skin cancer | n.s. | ||
| median (IQR) | 76.0 years (70.0–78.0) | 77.0 years (71.0–81.0) | |
| Primary site of skin cancer | 0.79 | ||
| Head and neck | 13 (86.7%) | 43 (72.9%) | |
| Trunk | 2 (13.3%) | 9 (15.3%) | |
| Extremities | 0 (0.0%) | 5 (8,5%) | |
| Mucosa | 0 (0.0%) | 1 (1.7%) | |
| unknown primary | 0 (0.0%) | 1 (1.7%) | |
| Median follow-up time (months, IQR) | 6.2 (2.3–13.4) | 6.0 (3.1–13.2) | n.s. |
| MCC (total) | 17 (100%) | 76 (100%) | |
| Gender | 0.82 | ||
| Male | 12 (70.6%) | 53 (69.7%) | |
| Female | 5 (29.4%) | 23 (30.3%) | |
| Age at diagnosis of skin cancer | n.s. | ||
| Median (IQR) | 70.0 years (63.0–78.5) | 71.0 years (62.7–78.0) | |
| Primary site of skin cancer | 0.61 | ||
| Head and neck | 5 (29.4%) | 20 (26.3%) | |
| Trunk | 4 (23.5%) | 13 (17.1%) | |
| Extremities | 7 (41.2%) | 29 (38.2%) | |
| Unknown primary | 1 (5.9%) | 14 (18.4%) | |
| Median follow-up time (months, IQR) | 8.2 (4.0–13.2) | 11.4 (4.1–19.1) | n.s. |
Characteristics of all investigated patients treated with immune checkpoint inhibition (ICI) for advanced skin cancer. Comparisons are given with respective p values for each skin cancer entity in n=84 patients with and n=392 patients without concomitant hematological malignancy. Percentages are given per column. Median follow-up times were calculated from start of ICI therapy until last observation or death.
cSCC, cutaneous squamous cell carcinoma; MCC, Merkel cell carcinoma; MM, malignant melanoma.